Literature DB >> 11289737

Papillary and follicular thyroid carcinoma.

M J Schlumberger1, M Torlantano.   

Abstract

Papillary and follicular thyroid carcinomas are among the most curable of all cancers. However, some patients are at high risk of recurrence or even death from their cancer. Most of these patients can be identified at the time of diagnosis using well-established prognostic indicators. The extent of initial treatment and follow-up should therefore be individualized. The early discovery of persistent and recurrent disease is based on the combined use of serum thyroglobulin determination and of total body scanning with 131I. The recent availability of recombinant human thyroid stimulating hormone has greatly improved the quality of the patient's life during follow-up. Treatment of recurrences is based mainly on surgery and 131I treatment. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11289737     DOI: 10.1053/beem.2000.0105

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Endocrinol Metab


  14 in total

1.  Metastatic papillary thyroid carcinoma and severe airflow obstruction.

Authors:  Christopher Manganaris; Steven Wittlin; Haodong Xu; Michael Gurell; Patricia Sime; Robert Matthew Kottmann
Journal:  Chest       Date:  2010-09       Impact factor: 9.410

2.  Quality of life-in patients with differentiated thyroid cancer at the general endocrinology clinics of the University Hospital of Puerto Rico.

Authors:  Mónica A Vega-Vázquez; Loida Gonzalez-Rodriguez; Eduardo J Santiago-Rodríguez; Anette Garcés-Domínguez; Lee-Ming Shum; Maribel Tírado-Gómez; Margarita Ramírez-Vick
Journal:  Bol Asoc Med P R       Date:  2015 Jan-Mar

3.  Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.

Authors:  Weiwei Cheng; Rengyun Liu; Guangwu Zhu; Hui Wang; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2016-01-11       Impact factor: 5.958

4.  Five-year longitudinal evaluation of quality of life in a cohort of patients with differentiated thyroid carcinoma.

Authors:  Massimo Giusti; Giulia Melle; Monica Fenocchio; Lorenzo Mortara; Francesca Cecoli; Valeria Caorsi; Diego Ferone; Francesco Minuto; Elda Rasore
Journal:  J Zhejiang Univ Sci B       Date:  2011-03       Impact factor: 3.066

5.  Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology.

Authors:  Myat Han Soe; Janet M Chiang; Robert R Flavell; Elham Khanafshar; Laura Mendoza; Hyunseok Kang; Chienying Liu
Journal:  J Clin Endocrinol Metab       Date:  2022-07-14       Impact factor: 6.134

6.  (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.

Authors:  Filippo Galli; Isabella Manni; Giulia Piaggio; Lajos Balogh; Bruce D Weintraub; Mariusz W Szkudlinski; Valerie Fremont; Rudi A J O Dierckx; Alberto Signore
Journal:  Thyroid       Date:  2014-06-20       Impact factor: 6.568

7.  Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo.

Authors:  Koji Tsumagari; Zakaria Y Abd Elmageed; Andrew B Sholl; Erik A Green; Saboori Sobti; Abdul Razzaq Khan; Abdulrahman Kandil; Fadi Murad; Paul Friedlander; A Hamid Boulares; Emad Kandil
Journal:  Endocr Relat Cancer       Date:  2018-01       Impact factor: 5.900

8.  Minimal extrathyroidal extension affects the prognosis of differentiated thyroid cancer: Is there a need for change in the AJCC classification system?

Authors:  Zeming Liu; Yihui Huang; Sichao Chen; Di Hu; Min Wang; Ling Zhou; Wei Zhou; Danyang Chen; Haifeng Feng; Wei Wei; Chao Zhang; Wen Zeng; Liang Guo
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

9.  Evaluation of Quality of Life in Patients with Differentiated Thyroid Cancer by Means of the Thyroid-Specific Patient-Reported Outcome Questionnaire: A 5-Year Longitudinal Study.

Authors:  Massimo Giusti; Stefano Gay; Lucia Conte; Francesca Cecoli; Lorenzo Mortara; Lara Vera; Eleonora Monti
Journal:  Eur Thyroid J       Date:  2019-07-24

10.  Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?

Authors:  Eugene Jeong; Joon-Kee Yoon; Su Jin Lee; Euy Young Soh; Jeonghun Lee; Hyeung Kyoo Kim; Young-Sil An
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.